Product: PPAR gamma Antibody
Catalog: AF6284
Description: Rabbit polyclonal antibody to PPAR gamma
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 57kDa; 58kD(Calculated).
Uniprot: P37231
RRID: AB_2835135

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(92%), Bovine(92%), Horse(100%), Sheep(92%), Rabbit(100%), Dog(100%)
Clonality:
Polyclonal
Specificity:
PPAR gamma Antibody detects endogenous levels of total PPAR gamma.
RRID:
AB_2835135
Cite Format: Affinity Biosciences Cat# AF6284, RRID:AB_2835135.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; OTTHUMP00000185032; OTTHUMP00000185036; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome proliferator-activated receptor gamma; PPAR gamma; PPAR-gamma; PPARG; PPARG_HUMAN; PPARG1; PPARG2; PPARgamma;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P37231 PPARG_HUMAN:

Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

Description:
The protein encoded by this gene is a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma.
Sequence:
MGETLGDSPIDPESDSFTDTLSANISQEMTMVDTEMPFWPTNFGISSVDLSVMEDHSHSFDIKPFTTVDFSSISTPHYEDIPFTRTDPVVADYKYDLKLQEYQSAIKVEPASPPYYSEKTQLYNKPHEEPSNSLMAIECRVCGDKASGFHYGVHACEGCKGFFRRTIRLKLIYDRCDLNCRIHKKSRNKCQYCRFQKCLAVGMSHNAIRFGRMPQAEKEKLLAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Dog
100
Rabbit
100
Pig
92
Bovine
92
Sheep
92
Xenopus
69
Zebrafish
62
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P37231 As Substrate

Site PTM Type Enzyme
Y78 Phosphorylation
Y95 Phosphorylation
Y102 Phosphorylation
K107 Sumoylation
S112 Phosphorylation P50750 (CDK9) , P45983 (MAPK8) , P50613 (CDK7) , Q02750 (MAP2K1) , P27361 (MAPK3) , P28482 (MAPK1)
K184 Ubiquitination
K185 Ubiquitination
T269 Phosphorylation
S273 Phosphorylation Q00535 (CDK5)
K395 Sumoylation

Research Backgrounds

Function:

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of ARNTL/BMAL1 in the blood vessels (By similarity).

(Microbial infection) Upon treatment with M.tuberculosis or its lipoprotein LpqH, phosphorylation of MAPK p38 and IL-6 production are modulated, probably via this protein.

PTMs:

O-GlcNAcylation at Thr-84 reduces transcriptional activity in adipocytes.

Phosphorylated in basal conditions and dephosphorylated when treated with the ligand. May be dephosphorylated by PPP5C. The phosphorylated form may be inactive and dephosphorylation at Ser-112 induces adipogenic activity (By similarity).

Subcellular Location:

Nucleus. Cytoplasm.
Note: Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

Subunit Structure:

Interacts with FOXO1 (acetylated form) (By similarity). Heterodimer with other nuclear receptors, such as RXRA. The heterodimer with the retinoic acid receptor RXRA is called adipocyte-specific transcription factor ARF6. Interacts with NCOA6 coactivator, leading to a strong increase in transcription of target genes. Interacts with coactivator PPARBP, leading to a mild increase in transcription of target genes. Interacts with NOCA7 in a ligand-inducible manner. Interacts with NCOA1 and NCOA2 LXXLL motifs. Interacts with ASXL1, ASXL2, DNTTIP2, FAM120B, MAP2K1/MEK1, NR0B2, PDPK1, PRDM16, PRMT2 and TGFB1I1. Interacts (when activated by agonist) with PPP5C. Interacts with HELZ2 and THRAP3; the interaction stimulates the transcriptional activity of PPARG. Interacts with PER2, the interaction is ligand dependent and blocks PPARG recruitment to target promoters. Interacts with NOCT. Interacts with ACTN4. Interacts (when in the liganded conformation) with GPS2 (By similarity). Interacts with CRY1 and CRY2 in a ligand-dependent manner (By similarity). In the absence of hormonal ligand, interacts with TACC1.

Family&Domains:

The 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.

Belongs to the nuclear hormone receptor family. NR1 subfamily.

Research Fields

· Environmental Information Processing > Signal transduction > AMPK signaling pathway.   (View pathway)

· Human Diseases > Neurodegenerative diseases > Huntington's disease.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Organismal Systems > Endocrine system > PPAR signaling pathway.

· Organismal Systems > Aging > Longevity regulating pathway.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

References

1). Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (PubMed: 31262330) [IF=11.3]

Application: WB    Species: human    Sample: AGS cells and MKN45 cells

Fig. 5| MUC17 protects GC cells against inflammatory stimulation by regulating the p38 pathway. a MUC17 regulated the expression of pJNK,pERK, and pp38 MAPK in MUC17 knocked-down AGS cells (left) and truncated MUC17 overexpressed MKN45 cells (right).b The effect of the p38 inhibitor SB203580 on the expression of NFκB pathway proteins and G2/M phase arrest markers in MUC17 knocked-down AGS cells (left) and truncated MUC17 overexpressed MKN45 cells (right).

2). Mechanical stretching can modify the papillary dermis pattern and papillary fibroblast characteristics during skin regeneration. Journal of Investigative Dermatology (PubMed: 35181299) [IF=6.5]

3). Genetic inhibition of FABP4 attenuated endoplasmic reticulum stress and mitochondrial dysfunction in rhabdomyolysis-induced acute kidney injury. LIFE SCIENCES (PubMed: 33434534) [IF=6.1]

Application: WB    Species: Mice    Sample: Kidney tissue

Fig. 4. FABP4 deficiency improved renal ER stress and mitochondrial dysfunction in rhabdomyolysis-induced AKI. (A) Immunoblot and quantitative analysis of ER stress related proteins; (B) immunofluorescence staining of ER stress related proteins; (C) ultrastructural changes of endoplasmic reticulum and mitochondria. (Red arrow: swelling of mitochondria; Blue arrow: widening of mitochondrial cristae; Green arrow: swelling of endoplasmic reticulum). *P < 0.05, **P < 0.01, ****P < 0.0001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

4). Therapeutic role of D-pinitol on experimental colitis via activating Nrf2/ARE and PPAR-γ/NF-κB signaling pathways. Food & Function (PubMed: 33625409) [IF=6.1]

Application: WB    Species: Mice    Sample:

Fig. 9 Effect of D-pinitol on PPAR-γ in colitis mice. (A) Representative photographs of PPAR-γ, P-P65, P65, P-IκBα, and IκBα. The relative protein levels of (B) PPAR-γ, (C) P-P65/P65 ratio, and (D) P-IκBα/IκBα ratio were measured. Data are expressed as the mean ± SEM. ##p < 0.01 versus the normal group; **p < 0.01 versus the DSS group. Δp < 0.05, ΔΔp < 0.01 versus the SASP group.

5). Adipose specific aptamer adipo-8 recognizes and interacts with APMAP to ameliorates fat deposition in vitro and in vivo. LIFE SCIENCES (PubMed: 32272180) [IF=6.1]

Application: WB    Species: mouse    Sample: adipose

Fig. 5.| Adipo-8 ameliorated fat deposition through interaction with APMAP: (I) expression of fat metabolism related proteins in adipose tissue of different groups: adipo-8 administration reduced aP2, PPAR-γ, and C/EBP-α in adipose tissue of High fat fed mice.

6). Nrf2 Deficiency Exacerbated CLP-Induced Pulmonary Injury and Inflammation through Autophagy- and NF-κB/PPARγ-Mediated Macrophage Polarization. Cells (PubMed: 36497185) [IF=6.0]

Application: IF/ICC    Species: Mice    Sample: RAW264.7 cells

Figure 9 Nrf2 overexpression in vitro promotes PPARγ but inhibits NF-κB nuclear translocation; n = 3 experiments per group. (A,B) Immunofluorescence staining of NF-κB and PPARγ in RAW264.7 cells in each group. (C,D) Western blot analyses of Nrf2, NF-κB, and PPARγ levels in both cytoplasm and nucleus. ** p < 0.01, *** p < 0.001.

Application: WB    Species: Mice    Sample: RAW264.7 cells

Figure 9 Nrf2 overexpression in vitro promotes PPARγ but inhibits NF-κB nuclear translocation; n = 3 experiments per group. (A,B) Immunofluorescence staining of NF-κB and PPARγ in RAW264.7 cells in each group. (C,D) Western blot analyses of Nrf2, NF-κB, and PPARγ levels in both cytoplasm and nucleus. ** p < 0.01, *** p < 0.001.

7). Identification of zinc finger protein Bcl6 as a novel regulator of early adipose commitment. Open Biology (PubMed: 27251748) [IF=5.8]

8). Clevudine attenuates bleomycin-induced early pulmonary fibrosis via regulating M2 macrophage polarization. International Immunopharmacology (PubMed: 34700113) [IF=5.6]

9). FGF9 Alleviates the Fatty Liver Phenotype by Regulating Hepatic Lipid Metabolism. Frontiers in Pharmacology (PubMed: 35517790) [IF=5.6]

Application: WB    Species: mouse    Sample: liver

FIGURE 2 | Knockdown of FGF9 in the liver of DIO mice exacerbated fatty liver phenotype.. (H) Representative Western blotting analysis of genes involved in lipid synthesis in mice as described in (A).

10). Genetic and pharmacological inhibition of fatty acid-binding protein 4 alleviated inflammation and early fibrosis after toxin induced kidney injury. International Immunopharmacology (PubMed: 33991998) [IF=5.6]

Application: IF/ICC    Species: Mice    Sample: HK2 cells

Fig. 5. Genetic deletion of Fabp4 suppressed P65 and Stat3 activation via enhancing Pparγ in toxin (FA/AA) induced nephropathy. (A) Immunofluorescence costaining of FABP4 and PPARγ in HK2 cells (n = 3) (400x, scale bar ~ 20 μm). (B) The protein expression by immunoblot analysis of FABP4 and PPARγ in mice, and (C) quantified by densitometry (n = 3). (D) The protein expression by immunoblot analysis of P65/P-P65 and Stat3/P-Stat3 in the kidneys, and (E) quantified by densitometry (n = 3). All data are represented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Application: WB    Species: Mice    Sample: HK2 cells

Fig. 5. Genetic deletion of Fabp4 suppressed P65 and Stat3 activation via enhancing Pparγ in toxin (FA/AA) induced nephropathy. (A) Immunofluorescence costaining of FABP4 and PPARγ in HK2 cells (n = 3) (400x, scale bar ~ 20 μm). (B) The protein expression by immunoblot analysis of FABP4 and PPARγ in mice, and (C) quantified by densitometry (n = 3). (D) The protein expression by immunoblot analysis of P65/P-P65 and Stat3/P-Stat3 in the kidneys, and (E) quantified by densitometry (n = 3). All data are represented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.